[Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience]
- PMID: 18588813
- DOI: 10.1157/13123836
[Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience]
Abstract
Introduction: Highly active antiviral therapy (HAART) results in a sharp decrease in HIV-related morbidity and mortality, but also induces adverse effects such as dyslipidemia, which is difficult treat because of drug interactions. Guidelines recommend lipid-lowering therapy with pravastatin or atorvastatin to reduce LDL cholesterol in these patients, and gemfibrozil or fenofibrate for treating hypertriglyceridemia. The use of statins in the management of dyslipidemia is complicated by drug interactions with some of the components of HAART. Rosuvastatin, a statin with minimal cytochrome P-450-mediated metabolism, could be an alternative option for this population.
Methods: Retrospective study to evaluate the efficacy and safety of rosuvastatin (10 mg/day) for 16 weeks in HAART-treated HIV-infected patients with dyslipidemia, and moderate to high cardiovascular risk. Results were analyzed with the Shapiro-Wilks, K-S Lilliefors, and sign tests. Percentages were analyzed with the chi-square test.
Results: Seventy-eight patients were started on rosuvastatin for dyslipidemia, 60 as single therapy. After 16 weeks of treatment, a significant median decrease was seen in both LDL-cholesterol and non-HDL cholesterol (31.3% reduction in LDL and 29.9% in non-HDL). The therapeutic goal for non-HDL was achieved in 65.8% of patients. The decrease in triglyceride levels was also significant (34.1%); 35% of subjects achieved the therapeutic goal. The drug was withdrawn in 2 patients because of myositis, and in 1 because of gastrointestinal intolerance. There were no differences in efficacy or toxicity between patients receiving protease inhibitors, non-nucleoside reverse transcriptase inhibitors, or fibrates.
Conclusion: Rosuvastatin was safe and effective for treating dyslipidemia in HAART-treated HIV-infected patients. Results were similar to those observed in the HIV-uninfected population.
Similar articles
-
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.Clin Infect Dis. 2011 Feb 1;52(3):387-95. doi: 10.1093/cid/ciq111. Epub 2010 Dec 28. Clin Infect Dis. 2011. PMID: 21189273 Free PMC article.
-
Are HIV positive patients resistant to statin therapy?Lipids Health Dis. 2007 Oct 24;6:27. doi: 10.1186/1476-511X-6-27. Lipids Health Dis. 2007. PMID: 17958912 Free PMC article.
-
Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.Arq Bras Cardiol. 2012 Nov;99(5):997-1007. doi: 10.1590/s0066-782x2012005000096. Epub 2012 Oct 30. Arq Bras Cardiol. 2012. PMID: 23108642 English, Portuguese.
-
Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.Cardiovasc Drug Rev. 2002 Winter;20(4):303-28. doi: 10.1111/j.1527-3466.2002.tb00099.x. Cardiovasc Drug Rev. 2002. PMID: 12481202 Review.
-
Efficacy and safety of rosuvastatin in treatment of dyslipidemia.Am J Health Syst Pharm. 2005 May 15;62(10):1033-47. doi: 10.1093/ajhp/62.10.1033. Am J Health Syst Pharm. 2005. PMID: 15901588 Review.
Cited by
-
Treatment of dyslipidemia in HIV.Curr Atheroscler Rep. 2015 Apr;17(4):493. doi: 10.1007/s11883-015-0493-x. Curr Atheroscler Rep. 2015. PMID: 25702057 Review.
-
Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients.Lipids Health Dis. 2015 Jun 19;14:57. doi: 10.1186/s12944-015-0054-x. Lipids Health Dis. 2015. PMID: 26087958 Free PMC article. Clinical Trial.
-
Managing dyslipidemia in HIV/AIDS patients: challenges and solutions.HIV AIDS (Auckl). 2014 Dec 17;7:1-10. doi: 10.2147/HIV.S46028. eCollection 2015. HIV AIDS (Auckl). 2014. PMID: 25565897 Free PMC article. Review.
-
Lipid-lowering efficacy of rosuvastatin.Cochrane Database Syst Rev. 2014 Nov 21;2014(11):CD010254. doi: 10.1002/14651858.CD010254.pub2. Cochrane Database Syst Rev. 2014. PMID: 25415541 Free PMC article.
-
Statin associated adverse reactions in Latin America: a scoping review.BMJ Open. 2021 Oct 1;11(10):e050675. doi: 10.1136/bmjopen-2021-050675. BMJ Open. 2021. PMID: 34598987 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical